Completed PHASE3 INTERVENTIONAL NCT00005887

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

A Phase III, Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy With or Without RSR13 in Patients With Brain Metastases

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions Metastatic Cancer

Interventions efaproxiral radiation therapy

Updated 7 times since 2017 Last updated: Aug 20, 2021 Started: Feb 29, 2000 Primary completion: Jan 31, 2003 Completion: Jan 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Metastatic Cancer, this trial is completed. The trial is conducted by Spectrum Pharmaceuticals, Inc and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Spectrum Pharmaceuticals, Inc

Data source: Spectrum Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Aviano, Italy , Baltimore, United States , Berkeley, United States , Bismarck, United States , Boca Raton, United States , Brussels (Bruxelles), Belgium , Budapest, Hungary , Buffalo, United States , Burlington, United States and 56 more locations